Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Development
Breast cancer drug Enhertu shows impressive results
by Gina Vitale
June 11, 2022
| A version of this story appeared in
Volume 100, Issue 21
Enhertu, a drug for people with HER2-low metastatic breast cancer, showed positive results in a Phase 3 trial. The antibody-drug conjugate, a joint effort of AstraZeneca and Daiichi Sankyo, reduced the risk of disease progression or death by 50% compared with chemotherapy. Shanu Modi, the trial’s principal investigator, said in a press release that this is the first demonstration of HER2-directed therapy providing “a survival benefit” to people with low HER2 expression.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter